TALKMED GROUP LIMITED (“ TalkMed ” or the “ Company ”) 6 th Annual General Meeting 25 April 2019
Disclaimer This presentation contains certain financial information and results of operation, and may also contain certain projections, plans, strategies, and objectives of the Company which are not statements of historical fact but would constitute “forward -looking statements” that reflect the Company’s current views with respect to future events and financial performance. These views expressed herein are based on a number of estimates and current assumptions which are subject to business, economic and political uncertainties and contingencies, as well as various risks which are in many cases outside the control of the Company, and which may change over time and may cause the Company’s future results to be materially different than expected or indicated by such statements. No assurance can be given that future events will occur, that projections will be achieved, or that the Company’s assumptions are correct. Such forward‐looking statements are not guarantees of future performance and accordingly, the actual results, financial condition, performance or achievements of the Company may differ materially from those anticipated by the Company in the forward-looking statements. The information contained herein is current only as of its date and shall not, under any circumstances, create any implication that such information is correct as of any time subsequent to the date hereof or that there has been no change in the financial condition or affairs of the Company since such date. Opinions expressed herein reflect the judgment of the Company as of the date of this presentation and may be subject to change. This presentation may be updated from time to time and there is no undertaking by the Company to post any such amendments or supplements to this presentation. The Company will not be responsible for any consequences resulting from the use of this presentation, nor any undue reliance placed upon any opinion or statement contained herein.
Agenda Financial Business and Summary and performance corporate update outlook
31 Dec 2018 31 Dec 2017 % Increase/ For the year ended (“FY2018”) (“FY2017”) (decrease) S $’m S $’m Revenue 61.28 61.36 (0.1%) PERFORMANCE Interest income 0.98 0.76 28.7% REVIEW FOR Other income 0.10 0.12 (13.3%) THE GROUP (1) Operating expenses (27.22) (21.88) 24.4% Share of loss of (1.14) (1.83) (37.8%) associate Profit before tax 34.00 38.53 (11.8%) Income tax expense (6.79) (7.34) (7.5%) Profit after tax (“PAT”) 27.21 31.19 (12.8%) (1) Defined as the Company, its subsidiaries and associate company 4
S$'m REVENUE 65.0 1.4 (2.3%) 1.7 (2.8%) BREAKDOWN 60.0 – FY2018 vs FY2017 55.0 59.9 (97.7%) 59.7 (97.2%) 50.0 45.0 40.0 FY2017 FY2018 Oncology Services Stem Cell Services 5
S$'m 20.0 19.0 18.4 19.0 17.5 18.0 17.0 17.1 QUARTERLY 16.2 15.9 17.0 16.2 16.0 REVENUE 16.0 15.1 15.0 14.1 14.0 14.0 13.0 12.1 12.0 11.0 10.0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 (1) (1) (1) (1) (2) FY16 FY16 FY16 FY16 FY17 FY17 FY17 FY17 FY18 FY18 FY18 FY18 FY19 (1) Defined as the financial year ended 31 Dec 2016 (2) Based on management accounts of the Group 6
S$'m 20.0 19.0 19.0 18.4 17.5 18.0 17.1 17.0 QUARTERLY 17.0 16.2 16.2 16.0 15.9 REVENUE 16.0 15.1 (Cont’d) 15.0 14.0 14.1 14.0 12.1 13.0 12.0 11.0 10.0 Q1 Q1 Q1 Q1 Q2 Q2 Q2 Q3 Q3 Q3 Q4 Q4 Q4 FY2016 FY2017 FY2018 FY2019 FY2016 FY2017 FY2018 FY2016 FY2017 FY2018 FY2016 FY2017 FY2018 7
FY2018 FY2017 % Increase/ For the year ended S $’m S $’m (decrease) OPERATING EXPENSES FOR Employee benefits expense (20.46) (16.16) 26.7% THE GROUP Cost of share-based (0.54) (0.49) 11.0% payments to employees Operating lease expense (1.90) (1.69) 12.5% Other operating expenses (4.32) (3.54) 21.9% Total operating expenses (27.22) (21.88) 24.4% 8
FY2018 (Total: 27.22) (In S$ ’m) OPERATING Singapore Cancer Centre Pte. Ltd. EXPENSES FOR 20.96 THE GROUP – By Entities Stem Med Pte. Ltd. ("Stem Med") 4.07 CellVec Pte. Ltd. TalkMed Other subsidiaries ("CellVec") 0.99 0.22 0.98 9
FY2018 (In S$ ’m) Stem Med (Total: 4.07) Employee Benefits 1.20 OPERATING Other Operating Expenses EXPENSES 2.49 Operating Lease – Stem Med & Expense 0.38 CellVec (In S$ ’m) CellVec (Total: 0.98) Other Operating Expenses 0.35 Employee Benefits 0.57 Operating Lease Expense 0.06 10
FY2018 vs FY2017: Increase of 4.30 (In S$ ’m) (see below for breakdown) Others 0.12 EMPLOYEE Higher remuneraton of Higher remuneration BENEFITS non-doctor employees of Founding Doctors 0.94 1.29 EXPENSE FOR THE GROUP Remuneration of newly-hired doctors 0.95 (1) Higher profit-sharing – FY2018 vs FY2017 payout to doctors 1.00 11 (1) Net of decrease in remuneration of doctor who resigned in FY18
87.4% S $’m 90% 30.0 30.0 30.0 DIVIDENDS 83.0% 28.0 30.0 24.0 80.2% 80.4% 78.0% 80% 20.0 70% 10.0 60% - FY2014 FY2015 FY2016 FY2017 FY2018 Amount of Dividend Paid Dividend Paid as a % of PAT 12
S$’m 54.1 60.0 41.3 22.1 30.0 HONG KONG 0.5 4.2 (1) INTEGRATED - (1.1) (1.8) (3.6) (3.0) (3.8) (2.9) (2) ONCOLOGY (6.1) (7.1) (11.9) (12.7) (1) (14.2) (1) CENTRE HOLDINGS (30.0) LIMITED (“HKH”) FY2015 FY2016 FY2017 FY2018 Revenue Earnings before interest, tax, depreciation and amortisation ("EBITDA") PAT TalkMed's share of losses (1) For the period from 22 September 2014 to 31 December 2015 (2) On 9 June 2015, TalkMed entered into a collaboration agreement in relation to the investment in HKH and accordingly, took up the losses in HKH for the period from 9 June to 31 December 2015 13
Agenda Business and Financial Summary and corporate performance outlook update
Jul BUSINESS AND He founded the Singapore Sarcoma Dr Richard Quek joined the Group in Consortium in 2013 and serves as the July 2018 as a Senior Consultant. CORPORATE co-chair for the annual Singapore Dr Quek was formerly the Deputy Sarcoma Symposium. UPDATES Head of the Division of Medical Dr Quek also founded the Asian Oncology at National Cancer Centre - Key Sarcoma Consortium (ASC) in 2015 Singapore and Program Director for Developments and continues to lead the ASC whose Medical Oncology Specialist main aims are to develop sarcoma Training, bringing with him over 20 research and education across Asia. years of research and clinical experience. Dr Quek has special interests in the management of sarcomas, gastrointestinal stromal tumours, melanomas and lymphomas. 15
Jul BUSINESS AND Dr Wong Chiung Ing joined the Group Dr Wong has received various in July 2018 as a Senior Consultant. awards, including the National CORPORATE Healthcare Group Researcher Dr Wong specialises in the diagnosis UPDATES Investigator Scientist Enabler Grant and treatment of adult cancers with a and the Excellent Service Gold Award special interest in breast and - Key from SPRING Singapore. gynaecological cancers. Developments She has been invited to present at Dr Wong was previously involved in numerous public symposiums in (cont’d) clinical and translational research, Singapore and in the region. particularly first-in-human clinical trials exploring novel therapies for patients with cancer and had presented and published her work in internationally renowned high- impact journals. 16
Aug BUSINESS AND CellVec, a 57%-owned subsidiary, was incorporated on 8 August 2018. The Company’s subsidiary, TalkMed CORPORATE Chongqing Pte. Ltd., entered into a CellVec is a Singapore-based cell and collaboration framework agreement UPDATES gene therapy manufacturer that with the People’s Government of focuses on the development of a viral Yongchuan District, Chongqing - Key vector technology platform. Municipality, on 28 August 2018. Developments Subsequent to the incorporation of This was with the intention of (cont’d) CellVec, the cellular and gene therapy establishing a Sino-Singapore division of Stem Med was transferred International Cancer Hospital in and consolidated into CellVec. Chongqing. More details about CellVec will be Discussions are still ongoing. provided in the later part of this presentation. 17
Mar BUSINESS AND Dr Lee Yuh Shan joined the Group as He is also a member of SingHealth CORPORATE a Senior Consultant in March 2019 Institutional Review Board and sat on several pharmaceutical advisory UPDATES Dr Lee specialises in malignant boards. haematology such as lymphoma, - Key Regionally, he is active and speaks myeloma and haematopoietic stem cells transplant. in many regional haematology Developments symposiums especially in chronic His outstanding achievements earned lymphocytic leukemia and (cont’d) him Gold and Star awards in 2013 lymphoma. and 2017 respectively, under He Singapore Health Quality Service contributes to lymphoma Awards. support group and Singapore World Lymphoma Day. 18
Recommend
More recommend
